Heart Centre and Department of Public Health and Clinical Medicine, Umea University, Sweden.
Int J Cardiol. 2011 Nov 17;153(1):31-5. doi: 10.1016/j.ijcard.2010.08.031. Epub 2010 Sep 16.
Coronary artery stenoses have been shown in various trials to be moderated by treatment with statins. A similar effect on coronary artery calcification has not been demonstrated. We therefore undertook meta-analyses of trials examining the effect of statin treatment on coronary artery stenoses and coronary artery calcification.
Literature searches identified five controlled trials suitable for inclusion in the analysis of the effect of statins (high dose versus either low dose or placebo) on coronary artery calcification and six trials suitable for inclusion in the analysis of the effect of statins on coronary artery stenoses.
All trials reported substantial and significant reductions in LDL-C with statin treatment which results in net reductions of LDL-C in the CAC and coronary stenoses trials of 1.0 mmol/L and 0.9 mmol/L, respectively. Analysis of the CAC trials did not demonstrate any effect of statins on the progression of calcification. In contrast, in the coronary stenoses trials there was a consistent moderation of stenosis severity progression with statins (p<0.0001).
Meta-analyses of the available trials have demonstrated a significant moderation of coronary stenoses associated with the statin-induced reduction in LDL-C. In contrast, there was no effect on coronary calcification despite a similar reduction in LDL-C levels. This suggests that the pathogenesis of the two conditions may be different, if not in aetiology, then certainly in their development. It further suggests that statin use to moderate arterial calcification is not effective.
在各种试验中已经证明,他汀类药物治疗可以减轻冠状动脉狭窄。但尚未证明他汀类药物治疗对冠状动脉钙化有类似的影响。因此,我们对研究他汀类药物治疗对冠状动脉狭窄和冠状动脉钙化影响的试验进行了荟萃分析。
文献检索确定了五项适合纳入他汀类药物(高剂量与低剂量或安慰剂)对冠状动脉钙化影响的分析的对照试验,以及六项适合纳入他汀类药物对冠状动脉狭窄影响的分析的试验。
所有试验均报告他汀类药物治疗可显著降低 LDL-C,这导致 CAC 和冠状动脉狭窄试验中 LDL-C 的净减少分别为 1.0mmol/L 和 0.9mmol/L。对 CAC 试验的分析并未显示他汀类药物对钙化进展有任何影响。相比之下,在冠状动脉狭窄试验中,他汀类药物治疗可显著减轻狭窄严重程度的进展(p<0.0001)。
对现有试验的荟萃分析表明,他汀类药物降低 LDL-C 可显著减轻与冠状动脉狭窄相关的病变。相比之下,尽管 LDL-C 水平相似,但对冠状动脉钙化没有影响。这表明两种情况的发病机制可能不同,如果不是病因,那么肯定在其发展过程中是不同的。这进一步表明,他汀类药物用于减轻动脉钙化的效果并不理想。